Surufatinib

Generic Name: Surufatinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₈N_₆O_₃S

CAS Number: 1308672-74-3

Unique Ingredient Identifier: B2K5L1L8S9

Background: Surufatinib is under investigation in clinical trial NCT02588170 (Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors).

Indication: 单药用于治疗无法手术切除的局部晚期或转移性、进展期非功能性、分化良好（G1、G2）的胰腺和非胰腺来源的神经内分泌瘤（pNETs）。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer

Phase 2

Recruiting

Conditions: Advanced Biliary Tract Cancer

Interventions: Drug: Surufatinib
Drug: Gemcitabine
Drug: Cisplatin
Drug: Durvalumab
Drug: Pembrolizumab

First Posted Date: 2024-11-27

Last Posted Date: 2024-11-27

Lead Sponsor: Dai, Guanghai

Target Recruit Count: 35

Registration Number: NCT06708858

Locations: 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China

Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation

Phase 2

Not yet recruiting

Conditions: ESCC
Biliary Tract Cancer
Gastric Cancer
Pancreas Cancer

Interventions: Drug: Surufatinib
Drug: Serplulimab
Drug: standard chemotherapy

First Posted Date: 2024-07-31

Last Posted Date: 2024-07-31

Lead Sponsor: RenJi Hospital

Target Recruit Count: 80

Registration Number: NCT06531291

Locations: 🇨🇳
Renji hospital, Shanghai, Shanghai, China

Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 2

Not yet recruiting

Conditions: Gastric Cancer
Gastro Esophageal Junction Cancer

Interventions: Drug: Surufatinib
Drug: Sintilimab
Drug: Oxaliplatin
Drug: S1

First Posted Date: 2024-06-07

Last Posted Date: 2024-06-07

Lead Sponsor: Fudan University

Target Recruit Count: 20

Registration Number: NCT06447636

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, China

Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation

Phase 2

Not yet recruiting

Conditions: NSCLC

Interventions: Drug: Surufatinib
Drug: Tislelizumab

First Posted Date: 2024-05-16

Last Posted Date: 2024-05-16

Lead Sponsor: National Cancer Center, China

Target Recruit Count: 29

Registration Number: NCT06414915

Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Phase 1

Not yet recruiting

Conditions: Biliary Tract Cancer

Interventions: Drug: Surufatinib
Drug: Durvalumab

First Posted Date: 2024-02-13

Last Posted Date: 2024-02-13

Lead Sponsor: China Medical University, China

Target Recruit Count: 30

Registration Number: NCT06255262

Locations: 🇨🇳
Anshan Cancer Hospital, Anshan, Liaoning, China
🇨🇳
The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China
🇨🇳
First Hospital of China Medical University, Shenyang, Liaoning, China

and more 1 locations

HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

Phase 2

Active, not recruiting

Conditions: Intrahepatic Cholangiocarcinoma

Interventions: Drug: HAIC+TAE
Drug: Tislelizumab
Drug: Surufatinib

First Posted Date: 2024-02-02

Last Posted Date: 2024-11-21

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 28

Registration Number: NCT06239532

Locations: 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China

A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors

Phase 2

Not yet recruiting

Conditions: Pancreatic Neuroendocrine Tumor

Interventions: Drug: Placebo
Drug: Surufatinib

First Posted Date: 2023-12-06

Last Posted Date: 2023-12-06

Lead Sponsor: Changhai Hospital

Target Recruit Count: 100

Registration Number: NCT06158516

Locations: 🇨🇳
Changhai Hospital, Shanghai, China

Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

Phase 2

Not yet recruiting

Conditions: Carcinoma
Gallbladder Cancer
Angiogenesis Inhibitors
Tislelizumab
Antineoplastic Agents, Immunological
Immunotherapy
Intrahepatic Cholangiocarcinoma
Surufatinib

Interventions: Drug: HAIC
Drug: Surufatinib
Drug: Tislelizumab

First Posted Date: 2023-11-18

Last Posted Date: 2023-11-18

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 41

Registration Number: NCT06134193

A Study of Surufatinib in the Treatment of Advanced Soft Tissue Sarcoma

Not Applicable

Not yet recruiting

Conditions: Soft Tissue Sarcoma Adult

Interventions: Drug: Surufatinib

First Posted Date: 2023-10-31

Last Posted Date: 2023-10-31

Lead Sponsor: Fudan University

Target Recruit Count: 29

Registration Number: NCT06110650

Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer

Phase 2

Recruiting

Conditions: Differentiated Thyroid Cancer

Interventions: Drug: surufatinib

First Posted Date: 2023-08-14

Last Posted Date: 2023-08-14

Lead Sponsor: Fudan University

Target Recruit Count: 32

Registration Number: NCT05989425

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy